Insider Selling: Quantum-Si (NASDAQ:QSI) Insider Sells $13,600.80 in Stock

Posted by Francis Steltz on Jun 24th, 2026

Quantum-Si Incorporated (NASDAQ:QSI – Get Free Report) insider John Vieceli sold 15,112 shares of Quantum-Si stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $0.90, for a total transaction of $13,600.80. Following the completion of the transaction, the insider directly owned 1,140,434 shares in the company, valued at approximately $1,026,390.60. This represents a 1.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Quantum-Si Stock Performance

Shares of Quantum-Si stock traded down $0.05 on Wednesday, reaching $0.83. The stock had a trading volume of 5,042,480 shares, compared to its average volume of 6,078,957. The business’s 50-day moving average price is $0.99 and its two-hundred day moving average price is $1.04. The stock has a market cap of $180.13 million, a P/E ratio of -1.62 and a beta of 3.18. Quantum-Si Incorporated has a fifty-two week low of $0.69 and a fifty-two week high of $3.10.

Quantum-Si (NASDAQ:QSI – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.30 million. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 47.35%. As a group, equities analysts forecast that Quantum-Si Incorporated will post -0.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

QSI has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. Canaccord Genuity Group decreased their target price on Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research note on Wednesday, March 4th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $1.00.

Check Out Our Latest Report on Quantum-Si

Hedge Funds Weigh In On Quantum-Si

A number of institutional investors and hedge funds have recently bought and sold shares of QSI. Invesco Ltd. raised its stake in Quantum-Si by 177.7% during the 1st quarter. Invesco Ltd. now owns 103,657 shares of the company’s stock valued at $124,000 after purchasing an additional 66,336 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Quantum-Si by 23.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,552 shares of the company’s stock worth $85,000 after purchasing an additional 13,546 shares during the last quarter. Millennium Management LLC bought a new position in shares of Quantum-Si during the 1st quarter worth about $4,721,000. JPMorgan Chase & Co. increased its holdings in shares of Quantum-Si by 15.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock worth $131,000 after purchasing an additional 9,005 shares during the period. Finally, Rhumbline Advisers raised its position in shares of Quantum-Si by 36.0% during the second quarter. Rhumbline Advisers now owns 203,967 shares of the company’s stock valued at $400,000 after buying an additional 53,994 shares during the last quarter. Institutional investors own 39.90% of the company’s stock.

Quantum-Si Company Profile

(Get Free Report)

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.